



Contact information

+800 40 20 00 35 International toll free
+1 855 983 52 29 US toll free
+41 844 00 44 88 International Charges apply
www.equateplus.com

Account information

User ID: 2759033

23 January 2024

Vinay Mahajan
Novartis Healthcare Pvt. Ltd.
Salarpuria-Sattva Knowledge City
Raidurg, Rangareddy District
MADHAPUR / HYDERABAD, RANGAREDDY 500 081
India

Confirmation of sell to cover

Transaction ID: TNOV240122007183

Type of order: MARKET

Execution date: 22 Jan 2024 15:32:00 CET

Settlement date: 24 Jan 2024

CUSIP: H5820Q150

ISIN: CH0012005267

Instrument: NOVN

Exchange: Best Execution

Delivery & Sell

Total quantity - Restricted stock award	101 units
---	-----------

Quantity sold to cover debits	45 units
-------------------------------	----------

Sale price	94.143189 CHF
------------	---------------

Remaining - Instruments	56 units
Sale proceeds to cover debits	4 236.44 CHF

Debits

Commissions	-30.00 CHF
-------------	------------

Exchange fees	-0.01 CHF
---------------	-----------

Payment fees	-8.00 CHF
--------------	-----------

Sale stamp tax	-3.18 CHF
----------------	-----------

Taxes - Total	-4 049.10 CHF
---------------	---------------

Total debits	-4 090.29 CHF
--------------	---------------

Net volume	56 units
------------	----------

Residual cash	146.15 CHF
---------------	------------

Foreign exchange

Residual cash	146.15 CHF
Exchange rate EUR	1.03567

Net amount in distribution currency	151.36 EUR
--	-------------------

Amount is paid to ICICI Bank Limited, 000401043279 / EUR

Value date: 24 January 2024

Net units will be credited to your EquatePlus portfolio.

Income calculation

FMV price	93.80 CHF
Income cost basis	0.00 CHF
Income per instrument	93.80 CHF
<hr/>	
Net - RSA plus sold quantity	101 units
Total income	9 473.80 CHF

Capital gain calculation

Sale price	94,143,189 CHF
Capital gain cost basis (FMV)	93.80 CHF
Capital gain per instrument	0.34 CHF
<hr/>	
Sold quantity	45 units
Total capital gain	15.44 CHF

Equatex does not provide legal, tax nor investment advice and makes no representations as to the tax treatment of plan instruments or the investment returns thereof, neither in general nor in relation to your specific circumstances. Past performance is not necessarily indicative of future performance. You should obtain independent advice on the suitability of the plans and the instruments before investing or transacting.

Tax treatment depends on your individual circumstances and may be subject to change over time. If the currency of a plan instrument or financial service is different from the currency of your domicile country, the return may increase or decrease as a result of currency fluctuations. It is possible that additional costs (including taxes) may be incurred, which are linked to the transactions, the plan instruments and/or the services listed herein and which are not reflected in this document.

If you believe that there is an error or omission in this document, please report it as soon as possible – and in any case no later than 30 days after the date of this document – to the Contact Centre. If you have any questions regarding this document, please contact the Contact Centre or your employer compensation department. You can find the definition of the financial terms used in this document in the glossary located in the 'Help: Information & Support' section of EquatePlus.

Transaction details - Income

Plan	Grant date	Quantity	FMV price	Total value	Income cost basis	Total cost basis	Total income
Novartis Select Program	20 Jan 2021	101	93.80 CHF	9 473.80 CHF	0.00 CHF	0.00 CHF	9 473.80 CHF

Transaction details - Capital gain

Plan	Grant date	Sale quantity	Sale price	Sale proceeds	Capital gain cost basis (FMV)	Total cost basis	Total capital gain
Novartis Select Program	20 Jan 2021	45	94.143189 CHF	4 236.44 CHF	93.80 CHF	4 221.00 CHF	15.44 CHF